Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24692748.
- Also identified by DOI 10.1136/bjophthalmol-2014-304902.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The management of antiplatelet and anticoagulant treatment can be challenging for the ophthalmic surgeon with the risk of impaired surgical view or potentially sight-threatening haemorrhage. With the advent of newer medications and the expanding usage of these drugs, there is a need for up-to-date guidance on the subject. This paper describes the current use of modern antiplatelet and anticoagulant drugs in the UK, and reviews the evidence of such treatments in the context of ophthalmic surgery. A multidisciplinary approach has been used to develop a guideline for the management of antiplatelet and anticoagulation treatment in elective ophthalmic surgery. Specifically, guidance is provided on when and how to stop antiplatelet and anticoagulant treatment and, importantly, when to seek specialist medical advice.
Medical subject headings
- Anticoagulants
- Elective Surgical Procedures
- Ophthalmologic Surgical Procedures
- Platelet Aggregation Inhibitors